Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome

Alimentary Pharmacology and Therapeutics - Tập 48 Số 10 - Trang 1044-1060 - 2018
Alexander C. Ford1,2, Lucinda A. Harris3, Brian E. Lacy4, Eamonn M.M. Quigley5, Paul Moayyedi6
1Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK
2Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
3Division of Gastroenterology and Hepatology, Mayo School of Medicine, Scottsdale, Arizona
4Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida
5Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas
6Gastroenterology Division, Health Sciences Center, McMaster University, Hamilton, Ontario, Canada

Tóm tắt

SummaryBackground

Irritable bowel syndrome (IBS) is a chronic functional bowel disorder. Disturbances in the gastrointestinal microbiome may be involved in its aetiology.

Aim

To perform a systematic review and meta‐analysis to examine the efficacy of prebiotics, probiotics, synbiotics and antibiotics in IBS.

Methods

MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to July 2017). Randomised controlled trials (RCTs) recruiting adults with IBS, comparing prebiotics, probiotics, synbiotics or antibiotics with placebo or no therapy were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardised mean difference with a 95% CI.

Results

The search identified 4017 citations. Data for prebiotics and synbiotics were sparse. Fifty‐three RCTs of probiotics, involving 5545 patients, were eligible. Particular combinations of probiotics, or specific species and strains, appeared to have beneficial effects on global IBS symptoms and abdominal pain, but it was not possible to draw definitive conclusions about their efficacy. There were five trials of similar design that used rifaximin in non‐constipated IBS patients, which was more effective than placebo (RR of symptoms persisting = 0.84; 95% CI 0.79‐0.90). Adverse events were no more common with probiotics or antibiotics.

Conclusions

Which particular combination, species or strains of probiotics are effective for IBS remains, for the most part, unclear. Rifaximin has modest efficacy in improving symptoms in non‐constipated IBS.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra1607547

10.1053/j.gastro.2016.02.031

10.1111/j.1572-0241.2007.01740.x

10.1016/j.cgh.2012.02.029

10.1053/j.gastro.2016.02.014

10.1016/S2468-1253(16)30023-1

10.1016/j.cgh.2006.11.025

10.1053/j.gastro.2006.05.053

10.1001/jama.292.7.852

10.1111/1574-6941.12184

10.1111/j.1365-2982.2012.01891.x

10.1136/gutjnl-2013-305994

10.1053/j.gastro.2007.04.005

10.1136/gutjnl-2011-301501

10.1053/j.gastro.2016.09.049

10.1038/nrgastro.2017.75

10.1038/nrgastro.2014.66

10.1136/gut.2009.205476

10.1136/gut.2006.108712

10.1016/j.cgh.2009.06.031

Williams MD, 2010, Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations, J Clin Gastroenterol, 44, 631

10.1136/gut.2008.167270

10.1038/ajg.2014.202

10.1038/ajg.2014.187

Brandt LJ, 2009, An evidence‐based systematic review on the management of irritable bowel syndrome, Am J Gastroenterol, 104, S8, 10.14309/00000434-200901001-00002

10.1038/s41395-018-0084-x

HigginsJPT GreenS.Cochrane handbook for systematic reviews of interventions: Version 5.1.0.www.cochrane-handbook.org2009. Accessed April 6 2018.

10.1016/0197-2456(86)90046-2

10.1002/sim.1186

10.1136/bmj.315.7109.629

10.1136/bmj.d4002

Kabir MA, 2011, Role of Saccharomyces boulardii in diarrhoea predominant irritable bowel syndrome, Mymensingh Med J, 20, 397

10.1155/2013/824605

10.1016/j.nut.2014.02.010

10.1111/apt.12787

Jafari E, 2014, Therapeutic effects, tolerability and safety of a multi‐strain probiotic in Iranian adults with irritable bowel syndrome and bloating, Arch Iran Med, 17, 466

10.1111/nmo.12320

10.1111/jgh.12322

10.1097/MEG.0000000000000094

10.3748/wjg.v20.i26.8709

10.1016/j.dld.2014.11.007

10.1007/s10620-014-3299-8

10.3164/jcbn.15-14

10.1097/MEG.0000000000000484

10.1177/2050640615602571

10.1111/nmo.13037

10.1053/j.gastro.2017.05.003

10.3748/wjg.v22.i48.10631

10.1053/j.gastro.2017.06.010

10.1093/ajcn/72.6.1570

10.1111/nmo.12911

10.1111/j.1365-2036.2008.03911.x

10.3109/02813438909103666

10.1111/j.1572-0241.2000.02015.x

10.1097/00042737-200110000-00004

10.1046/j.1365-2036.2003.01543.x

10.1111/j.1365-2036.2005.02579.x

10.1111/j.1365-2982.2005.00695.x

10.1016/j.clnu.2005.06.001

10.1053/j.gastro.2004.11.050

Kim YG, 2006, The effects of probiotics on symptoms of irritable bowel syndrome, Korean J Gastroenterol, 47, 413

Simren M, 2006, Effects of Lactobacillus plantarum 299V on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS)—a randomized double blind controlled trial, Gastroenterology, 130, A600

10.1111/j.1572-0241.2006.00734.x

10.1111/j.1365-2036.2007.03362.x

10.1016/j.gcb.2007.06.001

10.1111/j.1365-2982.2008.01156.x

10.1111/j.1365-2036.2007.03542.x

10.1007/s10620-007-0196-4

10.1111/j.1365-2036.2008.03818.x

10.1111/j.1365-2036.2008.03853.x

10.1055/s-2008-1027702

10.5009/gnl.2009.3.2.101

10.1111/j.1365-2036.2008.03848.x

10.1111/j.1365-2036.2009.04183.x

10.1097/MCG.0b013e318204593e

10.1111/j.1365-2036.2011.04633.x

10.1007/s12602-010-9059-y

10.1097/MCG.0b013e31820ca4d6

10.3109/00365521.2011.565066

10.1097/MCG.0b013e31823712b1

Cui S, 2012, Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double‐blind placebo‐controlled study, Int J Clin Exp Med, 5, 238

10.3748/wjg.v18.i17.2067

10.3748/wjg.v18.i30.4012

10.1155/2012/214102

10.1007/s00384-011-1363-9

10.3109/00365521.2013.825314

10.1186/1471-230X-13-45

10.1111/j.1443-9573.2004.00176.x

10.3748/wjg.v18.i33.4563

10.1097/MEG.0000000000000557

10.1053/j.gastro.2016.08.003

Lombardo L, 2015, A reason why lactose‐free diet can be clinically ineffective in lactose intolerance patients, United European Gastroenterol J, 3, A54

Pimentel M, 2003, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double‐blind, randomized, placebo‐controlled study, Am J Gastroenterol, 98, 412

10.1111/j.1572-0241.2006.00458.x

10.7326/0003-4819-145-8-200610170-00004

Lembo A, 2008, Rifaximin for the treatment of diarrhea‐associated irritable bowel syndrome: short term treatment leading to long term sustained response, Gastroenterology, 134, A545

10.1056/NEJMoa1004409

10.1111/apt.12735

10.1111/j.1572-0241.2000.03368.x

10.1038/ctg.2016.32

10.1080/19490976.2016.1215805

10.2147/CEG.S89999

10.1111/apt.12800

10.1038/nm1521

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 48 Số 10

1044-1060

Thông tin tác giả